U.S. grants Vidac Pharma patent offering broad protection of mode of action underlying its oncology drug candidates
September 19, 2024 01:00 ET
|
Vidac Pharma Holding PLC
London (UK), September 19 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class...
Vidac Pharma publishes results of next-generation drug candidate tests in human and murine tumor models
July 25, 2024 01:30 ET
|
Vidac Pharma Holding PLC
London (UK), July 25, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel...
Vidac Pharma receives US patent office Notice of Allowance for crucial compounds in its cancer drug candidates
June 03, 2024 01:30 ET
|
Vidac Pharma Holding PLC
London (UK), June 3, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel...
Vidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate
March 27, 2024 02:30 ET
|
Vidac Pharma Holding PLC
Vidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate London (UK), March 27, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G;...
Vidac Pharma secures approval for next phase of clinical study of lead asset in Cutaneous T-Cell Lymphoma
March 12, 2024 02:30 ET
|
Vidac Pharma Holding PLC
London (UK), March 12, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a...
Vidac Pharma présente une efficacité élevée dans plusieurs modèles de tumeurs solides pour son candidat médicament anticancéreux de nouvelle génération, et une synergie avec le traitement standard des organoïdes du cancer du foie
February 19, 2024 01:30 ET
|
Vidac Pharma Holding PLC
Londres (Royaume-Uni), 19 février 2024, 7:30 CET – Vidac Pharma Holding Plc (Hambourg et Stuttgart : T9G ; ISIN : GB00BM9XQ619 ; WKN : A3DTUQ) est une société biopharmaceutique d'oncologie de stade...
Vidac Pharma presents high efficacy in multiple solid tumor models for its next-generation cancer drug candidate and synergy with standard-of-care treatment in liver cancer organoids
February 19, 2024 01:30 ET
|
Vidac Pharma Holding PLC
London (UK), February 19, 2024, 7:30 am CET – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a...
Vidac Pharma annonce des données positives de l'analyse intermédiaire de phase 2a pour son produit phare VDA-1102 dans le traitement des Lymphomes T cutanés (LCT), une maladie rare.
January 29, 2024 02:00 ET
|
Vidac Pharma Holding PLC
London (UK), January 29, 2024 - Vidac Pharma Holdings Plc. (Hambourg et Stuttgart : T9G ; ISIN:GB00BM9XQ619 ; WKN : A3DTUQ), société biopharmaceutique d'oncologie de stade clinique, pionnière d'une...
Vidac Pharma reports positive interim Phase 2a data in orphan disease cutaneous T-cell lymphoma (CTCL) with lead asset VDA-1102
January 29, 2024 02:00 ET
|
Vidac Pharma Holding PLC
London (UK), January 29, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a groundbreaking...
Vidac Pharma va mener une étude de phase 2b du VDA-1102, son candidat médicament pour le traitement de la kératose actinique en collaboration avec CentroDerm
December 19, 2023 01:00 ET
|
Vidac Pharma Holding PLC
Londres (Royaume-Uni), 19 décembre 2023 – Vidac Pharma Holding Plc (Hambourg et Stuttgart : T9G ; ISIN : GB00BM9XQ619 ; WKN : A3DTUQ), société biopharmaceutique d'oncologie de stade clinique, a...